Related references
Note: Only part of the references are listed.Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Ezra Y. Rosen et al.
CLINICAL CANCER RESEARCH (2021)
Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens
Shumei Kato et al.
JCI INSIGHT (2021)
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
V Subbiah et al.
ANNALS OF ONCOLOGY (2021)
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer
V. Subbiah et al.
ANNALS OF ONCOLOGY (2021)
Immunotherapy in non-small cell lung cancer harbouring driver mutations
Alfredo Addeo et al.
CANCER TREATMENT REVIEWS (2021)
Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
Vivek Subbiah et al.
CLINICAL CANCER RESEARCH (2021)
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Justin F. Gainor et al.
LANCET ONCOLOGY (2021)
Acquired Resistance to KRASG12C Inhibition in Cancer
M. M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
Oliver Illini et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
From Tissue-Agnostic to N-of-One Therapies:(R)Evolution of the Precision Paradigm
Jacob J. Adashek et al.
TRENDS IN CANCER (2021)
State-of-the-Art Strategies for Targeting RET-Dependent Cancers
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
Benjamin J. Solomon et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
Jacob J. Adashek et al.
ONCOLOGIST (2020)
Advances in Targeting RET-Dependent Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2020)
Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Transcriptomic silencing as a potential mechanism of treatment resistance
Jacob J. Adashek et al.
JCI INSIGHT (2020)
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
J. J. Lin et al.
ANNALS OF ONCOLOGY (2020)
Personalized molecularly matched therapies for carcinomas of unknown primary is associated with improved outcomes
J. J. Adashek et al.
ANNALS OF ONCOLOGY (2020)
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
L. J. Wirth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
RET isoforms contribute differentially to invasive processes in pancreatic ductal adenocarcinoma
Eric Y. Lian et al.
ONCOGENE (2020)
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
Shumei Kato et al.
NATURE COMMUNICATIONS (2020)
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
Aparna Hegde et al.
ESMO OPEN (2020)
Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice
Jiyun Lee et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2020)
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature
Sara Baglivo et al.
ONCOLOGY AND THERAPY (2020)
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
Jacob J. Adashek et al.
TRENDS IN CANCER (2020)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations
Thereasa A. Rich et al.
CLINICAL CANCER RESEARCH (2019)
Efficacy of Immune Checkpoint Inhibition in RET Fusion Positive Non-Small Cell Lung Cancer Patients
A. Sireci et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2)
Maria Domenica Castellone et al.
ENDOCRINE-RELATED CANCER (2018)
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
Zofia Piotrowska et al.
CANCER DISCOVERY (2018)
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2017)
Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma
M. Amit et al.
ONCOGENE (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma
Chengzhong Lin et al.
CANCER LETTERS (2016)
Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer
Mehdi Hedayati et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2016)
RET mutation and increased angiogenesis in medullary thyroid carcinomas
Antonella Verrienti et al.
ENDOCRINE-RELATED CANCER (2016)
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma
Andreas M. Heilmann et al.
ONCOLOGY (2016)
A Novel Dual Kinase Function of the RET Proto-oncogene Negatively Regulates Activating Transcription Factor 4-mediated Apoptosis
Rozita Bagheri-Yarmand et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
RET revisited: expanding the oncogenic portfolio
Lois M. Mulligan
NATURE REVIEWS CANCER (2014)
RET is a potential tumor suppressor gene in colorectal cancer
Y. Luo et al.
ONCOGENE (2013)
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
M. M. Moura et al.
BRITISH JOURNAL OF CANCER (2009)
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer:: A 10-year follow-up study
Rossella Elisei et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas
S. Dvorakova et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
PTEN modulates GDNF/RET mediated chemotaxis and branching morphogenesis in the developing kidney
Doyeob Kim et al.
DEVELOPMENTAL BIOLOGY (2007)
Minireview: RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis
Raffaele Ciampi et al.
ENDOCRINOLOGY (2007)
RET/PTC activation in papillary thyroid carcinoma: European journal of endocrinology prize lecture
Massimo Santoro et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
RET tyrosine kinase signaling in development and cancer
E Arighi et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
The RET proto-oncogene in human cancers
SM Jhiang
ONCOGENE (2000)
The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease
MC Bordeaux et al.
EMBO JOURNAL (2000)
Share Paper
